Navigation Links
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Date:3/26/2008

study showed highly significant increases in physician confidence in their ability to identify structural abnormalities, the number of pancreatic duct segments visualized and improvement in the overall quality of the MRI images.

RG1068 is a synthetic version of human secretin, a natural gastrointestinal hormone involved in the process of digestion. Secretin has been used for many years by gastroenterologists in combination with endoscopy, an invasive procedure to evaluate and treat diseases of the pancreas and gallbladder. There are risks associated with the use of endoscopy, which have generated interest in the development of safer non-invasive tests to diagnose gastrointestinal disorders. The use of secretin in combination with a non- invasive procedure such as MRI can improve the detection of abnormalities and increase the diagnostic quality of the MRI image of the pancreas. The use of MRI is attractive for patient care as it can obviate the need for more risky invasive procedures.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that s
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Sanguine Biosciences – a biotechnology company ... recruitment – will use its proprietary mobile application ... Inc. find and recruit people diagnosed with Congenital ... to participate in voluntary research, which will be ... hopefully aid in informing the development of potential ...
(Date:11/18/2014)... and SAN DIEGO , ... HPPI), a clinical stage biopharmaceutical company that discovers, ... patients with cancer, announced today that it filed ... U.S. Food and Drug Administration (FDA) on Friday, ... covers HPPI,s proposed clinical development of a patented ...
(Date:11/18/2014)... 18, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... manuscript on Risk-Based Monitoring (RBM), " Evaluating ... Measure in Clinical Trials ," in the ... Regulatory Science  (TIRS) journal. Developed by TransCelerate,s ... the manuscript examines the value of Source ...
Breaking Medicine Technology:Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2HedgePath Pharmaceuticals Files IND Application 2HedgePath Pharmaceuticals Files IND Application 3HedgePath Pharmaceuticals Files IND Application 4TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3
... , , ... company leading the scientific research of neurogenesis using its proprietary ... central nervous system (CNS) diseases, announced today results from the ... dose buspirone and melatonin, for the treatment of major depressive ...
... , , HOUSTON, July ... the U.S. Food and Drug Administration ("FDA") has approved the company,s proposal ... patients treated with VNS Therapy(TM). , , ... of study subjects from 460 to 330 and completed enrollment of 331 ...
Cached Medicine Technology:Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression 2Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression 3Cyberonics Provides Update on Depression Post-Approval Study 2Cyberonics Provides Update on Depression Post-Approval Study 3
(Date:11/18/2014)... (PRWEB) November 18, 2014 Hawthorne cosmetic ... affordable for patients. Nearly 70 percent of Americans over the ... the age of 74, 25 percent are missing not just ... options are available, but only one offers a look, feel, ... , This special includes a complimentary consultation that allows patients ...
(Date:11/18/2014)... -- Routine screening for heart disease isn,t effective for ... at high risk for a heart attack, according to ... not help prevent heart attacks or help patients avoid ... pain that occurs when the heart doesn,t receive enough ... best way to manage risks for heart-related complications, the ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
(Date:11/18/2014)... Sorrel Sky Gallery welcomes jewelry artist ... of her beautiful, one-of-a-kind pieces. Just in time for the ... gallery, Friday, December 5 from 5 – 7:30 p.m. for ... artistic creations began at her grandmother’s kitchen table at a ... designs. She studied at the Gemological Institute of America in ...
(Date:11/18/2014)... By Dennis Thompson ... (HealthDay News) -- Daily low-dose aspirin therapy may not ... suggests. The study, which involved more than ... major difference in heart-related deaths or non-fatal heart attacks ... who didn,t. "It indicates that primary prevention ...
Breaking Medicine News(10 mins):Health News:Hawthorne Dentist, Dr. Yashari, is Now Making Dental Implants More Affordable for Patients 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 3Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2Health News:Elizabeth Showers Trunk Show & Personal Appearance Hosted by Sorrel Sky Gallery 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3
... to combat HIV/AIDS, President A P J Abdul Kalam today ... the deadly disease is still out of reach of the ... companies have done formidable job in bringing down the price ... this reduction does not make the drug affordable to the ...
... In a plush Bangkok ballroom one evening in May, ... on foie gras, oysters and sushi while they talked ... of Alaskan king crab, French wine and melt-in-your-mouth Parma ... ways of putting Bangkok on the international culinary map. ...
... of Australia's biggest bread companies is not happy with the ... acid. They are petitioning the state and federal// governments to ... proposal is to enhance the foliate levels in women of ... defects, such as spina bifida. ,If you ask ...
... Chulanont, has defended his government's move to allow the introduction ... worries over intellectual property rights in the kingdom. ... explain our action to other countries as well the world ... Health Minister Mongkol Na Songkhla will be traveling to the ...
... skin’s ability to replace the tissue it sloughs off is ... Harvard Medical School published// in the May 4 issue of ... not only for skin, but for many epithelial tissues including ... stem cells turns out to be the p63 gene, a ...
... in the journal Proceedings of the National Academy of ... antibiotic which inhibits the work of an enzyme that ... ,Although such so-called gene-for-gene interactions are thought ... a single gene in a pathogen targeting a single ...
Cached Medicine News:Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Thailand Unfazed As US Worries Over Copyright Violations 2Health News:Master Regulatory Gene of Epithelial Stem Cells Identified 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
... QuickSite model 1056K LV lead is ... to promote shorter procedure times, delivering ... and reliability., ,The QuickSite LV lead ... left ventricular lead, including such features ...
... a new generation locking nail system, bringing ... separate nailing systems to create a single, ... bone fractures. , ,Through the development ... approach, both in principle and in detail, ...
... Intramedullary fixation has greatly ... tibial fractures. The Biomet Low ... indicated in the treatment of ... metastatic disease with pathologic or ...
Medicine Products: